The value of [18F]PSMA-1007 PET/CT combined with mpMRI in diagnosing prostate cancer with PI-RADS 3–4 lesions
Runjie Shui, Jihui Li, Shushan Ge, Jinming Cao, Shengming Deng, Bin Zhang · 2026
Read The value of [18F]PSMA-1007 PET/CT combined with mpMRI in diagnosing prostate cancer with PI-RADS 3–4 lesions by Runjie Shui, Jihui Li, Shushan Ge, Jinming Cao, Shengming Deng, Bin Zhang (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13350630.txt.
Description
Runjie Shui and co-authors tested in 2026 whether PSMA PET/CT joined with multiparametric MRI lifts prostate cancer diagnosis. The focus was intermediate PI-RADS 3 to 4 lesions. There, benign and malignant disease are hardest to split. True sorting avoids needless biopsies. It also catches cancers that need treatment.
One hundred thirty-five patients scanned from early 2024 to late 2025 were studied in look-back. Fluorine-18 PSMA-1007 PET/CT was weighed against MRI. Age, antigen measures, prostate volume, and scan uptake values fed a multi-parameter model. The joined path beat either mode alone for spotting cancer in this murky group. The model gives a step toward fewer missed cancers and fewer needless biopsies.
Catalog record
| CREATOR | Runjie Shui, Jihui Li, Shushan Ge, Jinming Cao, Shengming Deng, Bin Zhang |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 41 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |